Endomag on the rise: unveiling our new headquarters with an award-winning royal visit

Photo montage of the new office opening

An exciting end to 2021 for Endomag culminated in a move to much larger headquarters to support our ambitious plans for 2022.

With over 200,000 breast cancer patients already treated with the Sentimag® platform across more than 45 countries, this new base on the Cambridge Science Park – the UK’s answer to ‘Silicon Valley’, nicknamed ‘Silicon Fen’ – will allow us to continue developing and evolving our world-leading technologies.

Eric Mayes, Endomag CEO, presenting Sentimag at the Queen's Award event in November 2021

So what's new?

Our new HQ features large laboratory spaces, to deliver on our ongoing commitment to technological research and development. 

Spacious working areas have been set up to support cross-team collaboration, both internally and alongside physicians, helping to understand their surgical requirements and deliver the solutions needed.

Meanwhile, the open-plan break out areas and lake view provide our ever-growing team with the space to refresh and re-energise, as we continue to build a great place to work.

A royal stamp of approval

Earlier in the year, we were honoured to be awarded our second Queen’s Award – this time for International Enterprise – recognising the global reach and distribution of our technologies.

To mark the office opening and the Queen’s Award recognition, local business leaders, partners, press and representatives for the Queen’s Award joined us to celebrate and see our new base first hand. 

Our guests, including the Lord Lieutenant Julie Spence, were provided with tours of the new facilities, including the lab, warehouse and meeting areas.

Here they were given a full hands-on demonstration of our Magseed® and Magtrace® technologies and talked through the procedures that patients around the world undergo every day.

The next generation

Our Chief Technology Officer, Quentin Harmer, then took the opportunity to present our new Sentimag® system, which will be initially launched in the United States, subject to FDA 510(K) approval. 

During this talk, Quentin touched upon the enhancements that have been made to the platform from the current model, and how feedback from surgeons and radiologists has played an important role in the development of this advanced localisation system.

Quentin Harmer, Endomag CTO, presenting Sentimag at the Queen's Award event in November 2021

Celebrating the opening of the new offices and our second Queen’s Award, surrounded by many of the people who have helped us to reach this stage, was a truly special experience. 

As of the time of this post, we’re halfway through January and our roadmap for 2022 is already looking like an exceptional level-up – for patients, for physicians and for all of us at Endomag.

We can’t wait for you to see what we have in store.